Stock Watch: All Bayer’s Roads Lead To Unpalatable
After A Spate Of Disasters, Few Good Options Remain
Investors reacted quite differently to Bayer’s first-quarter results and those of its licensing partner Regeneron. There are sound reasons for this. It seems unlikely that one will help the other.
